First-Episode Psychosis: Critical Management Issues during the First Two Years

REFERENCES

• Nuechterlein KH, Dawson ME, Gitlin M, Ventura J, Goldstein MJ, Snyder KS, et al. Developmental processes in schizo- phrenic disorders: longitudinal studies of vulnerability and stress. Schizophr Bull 1992;18:387–425.
   PubMed Web of Science ®Google Scholar
• Strub RL, Black FW. Neurobehavioral disorders: a clinical ap- proach. Philadelphia: Davis, 1988.
   Google Scholar
• Nopoulos P, Flashman L, Flaum M, Arndt S, Andreasen N. Stability of cognitive functioning early in the course of schizo- phrenia. Schizophr Res 1994;14:29–37.
   PubMed Web of Science ®Google Scholar
• Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE. Longitudinal neuropsychological follow-up study of pa- tients with first-episode schizophrenia. Am J Psychiatry 1999; 156:1336–41.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Koreen AR, Chakos M, Sheitman B, Woerner M, Alvir JM, et al. Factors influencing treatment response and outcome of first-episode schizophrenia: implications for under- standing the pathophysiology of schizophrenia. J Clin Psychi- atry 1996;57(suppl 9):5–9.
   Google Scholar
• Geddes JR, Black RJ, Whalley LJ, Eagles JM. Persistence of the decline in the diagnosis of schizophrenia among first ad- missions to Scottish hospitals from 1969 to 1988. Br J Psychia- try 1993;163:620–6.
   Google Scholar
• Eaton WW, Thara R, Federman B, Melton B, Liang KY. Struc- ture and course of positive and negative symptoms in schizo- phrenia. Arch Gen Psychiatry 1995;52:127–34.
   PubMed Web of Science ®Google Scholar
• Lieberman JA, Alvir JM, Woerner M, Degreef G, Bilder RM, Ashtari M, et al. Prospective study of psychobiology in first- episode schizophrenia at Hillside Hospital. Schizophr Bull 1992;18:351–71.
   PubMed Web of Science ®Google Scholar
• Koreen AR, Siris SG, Chakos M, Alvir J, Mayerhoff D, Lieber- man JA. Depression in first-episode schizophrenia. Am J Psy- chiatry 1993;150:1643–8.
   PubMed Web of Science ®Google Scholar
• Tohen M, Stoll AL, Strakowski SM, Faedda GL, Mayer PV, Goodwin DC, et al. The McLean First-Episode Psychosis Proj- ect: six-month recovery and recurrence outcome. Schizophr Bull 1992;18:273–82.
   PubMed Web of Science ®Google Scholar
• Rolfe TJ, McGorry P, Cocks J, Longley T, Plowright D. Canna- bis use in first episode psychosis: incidence and short term outcome [Abstract]. Schizophr Res 1999;36:313.
   Web of Science ®Google Scholar
• Addington J. Early intervention strategies for comorbid can- nabis use and psychosis. Proceedings of the Inaugural Inter- national Cannabis and Psychosis Conference, Melbourne, Aus- tralia, 1999:7–14.
   Google Scholar
• Cantwell R, Brewin J, Glazebrook C, Dalkin T, Fox R, Medley I, et al. Prevalence of substance misuse in first-episode psycho- sis. Br J Psychiatry 1999;174:150–3.
   PubMed Web of Science ®Google Scholar
• Grech A, Van Os J, Murray RM. Influence of cannabis on the outcome of psychosis [Abstract]. Schizophr Res 1999;36:41.
   Google Scholar
• Linszen DH, Dingemans PM, Lenior ME. Cannabis abuse and the course of recent-onset schizophrenic disorders. Arch Gen Psychiatry 1994;51:273–9.
   PubMed Web of Science ®Google Scholar
• Drake RE, Xie H, McHugo GJ, Green AI. The effects of cloza- pine on alcohol and drug use disorders among patients with schizophrenia. Schizophr Bull 2000;26:441–9.
   PubMed Web of Science ®Google Scholar
• Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI. Effects of clozapine on substance use in patients with schizo- phrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol 2000,20:94–8.
   Google Scholar
• Green AI, Zimmet SV, Strous RD, Schildkraut JJ. Clozapine for comorbid substance use disorder and schizophrenia: do pa- tients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? Harvard Rev Psychiatry 1999;6:287–96.
   PubMed Web of Science ®Google Scholar
• Wirshing DA. Weight gain associated with novel antipsychotic medications. Prim Psychiatry 2000;7:59–62.
   Google Scholar
• Masand PS, Blackburn GL, Ganguli R, Goldman LS, Gorman J, Greenberg I, et al. Weight gain associated with the use of antipsychotic medications. J Clin Psychiatry Audiogr Ser 1999;2.
   Google Scholar
• Wirshing DA, Spellberg BJ, Erhart SM, Marder SR, Wirshing WC. Novel antipsychotics and new onset diabetes. Biol Psychi- atry 1998;44:778–83.
   PubMed Web of Science ®Google Scholar
• Green AI, Patel JK, Goisman RM, Allison DB, Blackburn G. Weight gain from novel antipsychotic drugs: need for action. Gen Hosp Psychiatry 2000;22:224–35.
   PubMed Web of Science ®Google Scholar
• Reinstein MJ, Sirotovskaya LA, Jones LE, Mohan S, Chasa- nov MA. Effect of clozapine-quetiapine combination therapy on weight and glycemic control. Clin Drug Invest 1999;18:99–104.
   Google Scholar
• Perkins DO. Adherence to antipsychotic medications. J Clin Psychiatry 1999;60(suppl 21):25–30.
   Google Scholar
• Allison DB, Mentore JL, Heo M, Chandler LP, Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a com- prehensive research synthesis. Am J Psychiatry 1999;156:1686–96.
   PubMed Web of Science ®Google Scholar
• Allison DB, Fontaine KR, Heo M, Mentore JL, Cappelleri JC, Chandler LP, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215–20.
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Hogarty GE, Steingard S. Optimal dose of neuro- leptic in acute schizophrenia: a controlled study of the neuro- leptic threshold and higher haloperidol dose. Arch Gen Psychi- atry 1991;48:739–45.
   PubMed Web of Science ®Google Scholar
• Aguilar EJ, Keshavan MS, Mart´ınez-Quiles MD, Herna´ ndez J, Go´mez-Beneyto M, Schooler NR. Predictors of acute dysto- nia in first-episode psychotic patients. Am J Psychiatry 1994; 151:1819–21.
   Google Scholar
• Zhang-Wong J, Zipursky RB, Beiser M, Bean G. Optimal halo- peridol dosage in first-episode psychosis. Can J Psychiatry 1999;44:164–7.
   PubMed Web of Science ®Google Scholar
• Kopala LC, Good KP, Honer WG. Extrapyramidal signs and clinical symptoms in first-episode schizophrenia: response to low dose risperidone. J Clin Psychopharmacol 1997;17:308–13.
   PubMed Web of Science ®Google Scholar
• Glazer WM. Review of incidence studies of tardive dyskinesia associated with typical antipsychotics. J Clin Psychiatry 2000; 61(suppl 4):15–20.
   Google Scholar
• McGorry PD. Recommended haloperidol and risperidone doses in first-episode psychosis [Letter]. J Clin Psychiatry 1999;60: 794.
   PubMed Web of Science ®Google Scholar
• Kopala LC, Fredrikson D, Good KP, Honer WG. Symptoms in neuroleptic-na¨ıve, first-episode schizophrenia: response to risperidone. Biol Psychiatry 1996;39:296–8.
   PubMed Web of Science ®Google Scholar
• Keshavan MS, Schooler NR, Sweeney JA, Haas GL, Pettegrew JW. Research and treatment strategies in first-episode psycho- ses: the Pittsburgh experience. Br J Psychiatry 1998; 172(suppl 33):60–5.
   Google Scholar
• Lieberman J, Sanger T, Tohen M. Olanzapine and haloperidol treatment in first episode schizophrenia and schizoaffective disorder: 12-week outcome of a two year randomized double blind trial. Presented at the Second International Conference on Early Psychosis, New York City, April 2000.
   Google Scholar
• Emsley RA. Risperidone in the treatment of psychotic pa- tients: a double-blind multicenter study. Schizophr Bull 1999; 25:721–9.
   PubMed Web of Science ®Google Scholar
• Meltzer HY, McGurk SR. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 1999;25:233–55.
   PubMed Web of Science ®Google Scholar
• Bilder RM, Goldman RS, Robinson D, Reiter G, Bell L, Bates JA, et al. Neuropsychology of first-episode schizophrenia: ini- tial characterization and clinical correlates. Am J Psychiatry 2000;157:549–59.
   PubMed Web of Science ®Google Scholar
• Green MF. What are the functional consequences of neurocog- nitive deficits in schizophrenia? Am J Psychiatry 1996;153:321–30.
   PubMed Web of Science ®Google Scholar
• McGurk SR. Neurocognition as a determinant of employment status in schizophrenia. J Psych Prac 2000;6:190–6.
   PubMedGoogle Scholar